Formic Acid

Formic Acid

SCHEMBL30727697

O=CO.O=c1[nH]cc(-c2cc3c(N4CCC(OCc5ccccn5)C4)ncnc3s2)c(=O)[nH]1

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPL P06858 1/20 0.39
LIPC P11150 1/20 0.39
LIPG Q9Y5X9 1/20 0.39
ALDH1A1 P00352 10/20 0.36
KDM4E B2RXH2 10/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
MAPT P10636 4/20 0.36
MAPK1 P28482 4/20 0.36
RXFP1 Q9HBX9 2/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
PDE10A Q9Y233 1/20 0.36
MEN1 O00255 5/20 0.34
GAA P10253 4/20 0.34
KMT2A Q03164 4/20 0.34
MCL1 Q07820 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
KRAS P01116 1/20 0.34
EGFR P00533 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30727616 0.96 LPL (0.40) LPLLIPCLIPGALDH1A1KDM4E
SCHEMBL31399866 0.86 ALDH1A1 (0.42) ALDH1A1KDM4ESMN1; SMN2MAPTMAPK1
SCHEMBL30727648 0.82 KDM4E (0.37) LIPGALDH1A1KDM4ESMN1; SMN2MAPT
Formic Acid SCHEMBL30727763 0.80 KIT (0.36) ALDH1A1MAPK1KRASPOLBHTT
SCHEMBL30727599 0.78 KDM4E (0.37) ALDH1A1KDM4ESMN1; SMN2MAPK1MEN1
SCHEMBL30727708 0.77 LRRK2 (0.40) ALDH1A1KDM4ESMN1; SMN2MAPTMAPK1
SCHEMBL30727577 0.76 KIT (0.38) ALDH1A1KDM4EMAPK1MEN1KMT2A
SCHEMBL30727802 0.76 ENPP1 (0.40) ALDH1A1KDM4ESMN1; SMN2MAPTMAPK1
SCHEMBL30727686 0.75 PDE10A (0.42) LPLLIPCLIPGALDH1A1KDM4E
SCHEMBL30727620 0.74 PDE10A (0.41) PDE3BPDE3APDE10AKRASLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340565-A1 CD73 INHIBITOR COMPOUNDS ADORX THERAPEUTICS LTD (GB) 2025-11-06 US disclosed
EP-4532495-A1 CD73 INHIBITOR COMPOUNDS Adorx therapeutics Limited (GB) 2025-04-09 EP disclosed
CN-119585273-A CD73 inhibitor compounds 阿道尔克斯治疗有限公司 2025-03-07 CN disclosed
WO-2023233130-A1 CD73 INHIBITOR COMPOUNDS AdoRx Therapeutics Limited (GB) 2023-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340565-A1 CD73 INHIBITOR COMPOUNDS ENTPD5, ENTPD1, NT5E LPL 2411/4885LIPC 2674/4885LIPG 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.